The Immuno-Oncology segment focuses on the development of novel therapeutics for the treatment of various cancers. Vaccinex's primary focus in this area is pepinemab, a humanized monoclonal antibody targeting SEMA4D. Pepinemab is being evaluated in Phase 1 and 2 clinical trials for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), osteosarcoma, and melanoma. Research and development activities include clinical trial design, patient enrollment, and data analysis to assess the efficacy and safety of pepinemab. The company utilizes advanced antibody engineering and immunological techniques. The goal is to improve patient outcomes by enhancing the immune response against cancer cells. Vaccinex aims to establish a strong market position by offering innovative cancer therapies with the potential to address unmet medical needs. Future opportunities include expanding the clinical trials to include additional cancer types and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial guidelines. Partnerships with other pharmaceutical companies and research institutions are crucial for advancing the development and commercialization of pepinemab.

This segment is dedicated to developing treatments for slowly progressive neurodegenerative diseases, with a primary focus on pepinemab. Pepinemab is being evaluated in clinical trials for Huntington's disease and Alzheimer's disease. Research and development efforts include conducting clinical trials, analyzing patient data, and refining therapeutic strategies. Vaccinex utilizes advanced techniques in antibody development and neurological research. The aim is to slow disease progression and improve the quality of life for patients. The company's market positioning involves targeting diseases with significant unmet medical needs. Future opportunities include expanding the clinical trials to include other neurodegenerative diseases and exploring combination therapies. Regulatory and clinical aspects involve obtaining necessary approvals and adhering to clinical trial protocols. Collaborations with research institutions and patient advocacy groups are essential for advancing the development of these therapies.

This segment focuses on the development of therapies for autoimmune disorders, including multiple sclerosis (MS). Vaccinex is developing VX5, a human antibody to CXCL13, and exploring its potential in treating MS and other autoimmune conditions. Research and development activities include preclinical studies, antibody engineering, and target validation. The company employs advanced immunological and molecular biology techniques. The goal is to modulate the immune system and reduce the severity of autoimmune diseases. Vaccinex aims to establish a strong market position by offering innovative therapies for autoimmune disorders. Future opportunities include expanding the research pipeline to include additional autoimmune diseases and exploring combination therapies. Regulatory and clinical aspects involve navigating the regulatory approval process and conducting clinical trials. Partnerships with research institutions and pharmaceutical companies are crucial for advancing the development and commercialization of these therapies.